Originally published by our sister publication Infectious Disease Special Edition
By Ethan Covey
A novel combination of bictegravir (BIC; Biktarvy, Gilead) and lenacapavir (LEN, Sunlenca, Gilead) appears highly effective in maintaining viral suppression over 48 weeks among virologically suppressed people with HIV who were switched from a complex antiretroviral therapy (ART), according to findings presented during the “ART nouveau” session at AIDS 2024 (abstract OAB2602).
The study